Dr. Rini Explains the Axitinib Integration Process

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio discusses the integration of axitinib into the clinical practice, initially, he believes, in the refractory setting and soon in the front-line as new trial results come in, the most recent trial completed was the AXIS 1032 phase III trial comparing axitinib to sorafenib in the second-line setting for metastatic renal cell carcinoma (mRCC) which found axitinib to be superior to sorafenib.